Senior Law Lecturer, Western Sydney University
Dr Patrick Foong has taught law for many years in different countries and has spent the last fifteen years in the Australasian region. Currently, he is the academic programme advisor, and senior lecturer, at the School of Law at Western Sydney University, Australia.
A Supreme Court decision affirms the FDA's regulatory oversight of stem-cell-based treatments. Dr Patrick Foong explains the implications for stem cell clinics and their patients...
The Federal Trade Commission and Attorney General's Consumer Protection Division of Georgia collaborated to bring legal action against stem cell companies...
The significance of the appeal court's decision in California to rule in favour with the FDA is that it reaffirms the FDA's authority over bogus stem cell treatments...
The unanimous verdict of a Florida jury that the Tampa-based Lung Institute was guilty of deceptively and unfairly selling stem cell treatments that caused damage to patients, could prove to be a landmark case in the fight against unproven stem cell treatments…
China recently updated its regulation on human genome editing, a positive outcome after Dr He Jiankui created the world's first genome-edited babies. However, do these regulations go far enough?...
The latest genome editing approaches and treatments, as well as ethical issues and equitable access, were discussed at the Third International Summit on Human Genome Editing...
The recent court ruling that the US FDA's powers do not extend to regulating some stem cell treatments is a blow for those hoping for better regulation of unproven treatments, argues Dr Patrick Foong...
StemGenex, a now-closed stem cell clinic in San Diego, California, has agreed to pay out US$3.65 million as a class action settlement to its former patients for ineffective stem cell treatments they received...
In the USA, clinics offering stem cell therapies not approved by the US Food and Drug Administration expanded four-fold in just five years...
Is an international conversation on the 14-day rule needed in the light of the development of iBlastoids?...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.
